Brokerages Set Evolent Health, Inc. (NYSE:EVH) Price Target at $21.92

Evolent Health, Inc. (NYSE:EVH) has received a consensus rating of “Buy” from the thirteen analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $18.54.

A number of research analysts have recently weighed in on EVH shares. BTIG Research cut their price target on Evolent Health from $36.00 to $29.00 and set a “buy” rating on the stock in a research note on Tuesday, December 3rd. Royal Bank of Canada cut their target price on Evolent Health from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 14th. UBS Group decreased their target price on Evolent Health from $27.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, January 16th. Oppenheimer cut their price target on shares of Evolent Health from $28.00 to $18.00 and set an “outperform” rating on the stock in a research report on Friday. Finally, Stephens decreased their price objective on shares of Evolent Health from $16.00 to $12.00 and set an “equal weight” rating for the company in a report on Tuesday, January 21st.

Evolent Health Price Performance

Shares of EVH stock opened at $10.11 on Monday. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -11.10 and a beta of 1.45. Evolent Health has a 12 month low of $9.74 and a 12 month high of $35.00. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. The stock has a 50-day moving average price of $11.45 and a 200 day moving average price of $20.39.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Thursday, November 7th. The technology company reported ($0.08) EPS for the quarter, missing the consensus estimate of $0.30 by ($0.38). Evolent Health had a positive return on equity of 6.30% and a negative net margin of 2.93%. The business had revenue of $621.40 million for the quarter, compared to analyst estimates of $625.58 million. During the same quarter in the prior year, the firm earned $0.19 EPS. Research analysts expect that Evolent Health will post 0.26 EPS for the current year.

Institutional Investors Weigh In On Evolent Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Royce & Associates LP bought a new position in shares of Evolent Health during the 3rd quarter worth approximately $7,070,000. Foundry Partners LLC bought a new position in Evolent Health in the third quarter valued at $10,042,000. Salem Investment Counselors Inc. increased its stake in Evolent Health by 53.0% in the 4th quarter. Salem Investment Counselors Inc. now owns 350,155 shares of the technology company’s stock valued at $3,939,000 after buying an additional 121,369 shares during the last quarter. Harbor Capital Advisors Inc. lifted its position in Evolent Health by 140.0% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 422,421 shares of the technology company’s stock worth $11,946,000 after buying an additional 246,400 shares in the last quarter. Finally, Nordea Investment Management AB boosted its stake in shares of Evolent Health by 7.0% during the 4th quarter. Nordea Investment Management AB now owns 130,453 shares of the technology company’s stock worth $1,469,000 after buying an additional 8,552 shares during the last quarter.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.